

## Treatment of LTBI

*At risk: PPD+ (≥5 mm induration) without prior treatment of LTBI*

Preferred Regimen	Alternative Regimen**	Special Cases
<p>INH 5mg/kg per day, max dose of 300mg/day + pyridoxine 50 mg/day, x 9 months</p> <p>INH 15 mg/kg up to a dose of 900+ pyridoxine 100 mg 2x/wk, x 9 months</p>	<p>RIF 10 mg/kg up to 600 mg per day mg/day + PZA 15-20 mg/kg/day x 2 months (see CAUTION below)</p> <p>RIF 10 mg/kg up to 600 mg/day x 4 months</p> <p><i>**Patients receiving PI or NNRTI should not receive RIF. With some antiretrovirals, rifabutin can be substituted for RIF with an antiretroviral dose adjustment. Consult an expert.</i></p>	<p><b>INH-resistant strain:</b> RIF 10 mg/kg up to 600 mg/day x 4 months. RIF 10 mg/kg up to 600 mg per day + PZA 15-20 mg/kg/day x 2 months (see CAUTION below)</p> <p><b>INH- and RIF-resistant strain:</b> Treat in consultation with an expert in MDR TB.</p> <p><b>Pregnancy:</b> Use INH regimen.</p>
<p><b>*CAUTION:</b> Cases of severe liver injury, some fatal, have been associated with the use of RIF/PZA for the treatment of LTBI. The RIF/PZA regimen is contraindicated in those with alcoholism and those with liver injury during prior use of INH. Avoid two-month regimens except perhaps in high-risk cases with impending parole or release who are unlikely to continue therapy after release. Full information on recommendations concerning RIF/PZA are available in the August 2001 MMWR 50 (34): 733-735 or at <a href="http://www.cdc.gov/mmwr/PDF/wk/mm5034.pdf">http://www.cdc.gov/mmwr/PDF/wk/mm5034.pdf</a></p>		
<p><b>Monitoring:</b> Baseline bilirubin, AST &amp; ALT, add CBC if treated w/RIF or RFB. Repeat tests if baseline tests are abnormal or if there are symptoms of hepatitis. Recipients of INH or RIF alone: symptom review monthly. For those receiving PZA plus RIF or RFB, more careful monitoring to include LFTs at two, four and six weeks.</p>		
<p>EMB = ethambutol, INH = isoniazid, PZA = pyrazinamide, RFB = rifabutin, RIF = rifampin, SM = streptomycin</p>		

*Adapted from Bartlett JG, Gallant JE. Medical Management of HIV Infection 2001-2002 Edition.*